

185. Palladini G, Kastiris E, Maurer MS, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. *Blood*. 2020;136(1):71-80. doi: 10.1182/blood.2019004460. PMID: 32244252; PMCID: PMC7332897.
186. Palladini G, Milani P, Malavasi F, et al. Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis. *Cells*. 2021;10(3):545. doi: 10.3390/cells10030545. PMID: 33806310; PMCID: PMC7998921.
187. Kastiris E, Palladini G, Minnema M, et al. Subcutaneous Daratumumab + cyclophosphamide, Bortezomib, and Dexamethasone (CYBORD) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Primary Results from the Phase 3 ANDROMEDA Study. EHA Meeting 2020, 13 June 2020. [accessed on 4 March 2021]. Available online: <https://ehaweb.org/meetings/>.
188. Khouri J, Kin A, Thapa B, et al. Daratumumab proves safe and highly effective in AL amyloidosis. *Br. J. Haematol.* 2019;185:342-344. doi: 10.1111/bjh.15455.
189. Abeykoon JP, Zanwar S, Dispenzieri A, et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. *Leukemia*. 2019;33:531-536. doi: 10.1038/s41375-018-0262-2.
190. Schwotzer R, Manz MG, Pederiva S, et al. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. *Hematol. Oncol.* 2019;37:595-600. doi: 10.1002/hon.2677.
191. Godara A, Siddiqui NS, Lee LX, et al. Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement. *Clin. Lymphoma Myeloma Leuk.* 2020;20:184-189. doi: 10.1016/j.clml.2019.10.019.
192. Chung A, Kaufman GP, Sidana S, et al. Organ responses with daratumumab therapy in previously treated AL amyloidosis. *Blood Adv.* 2020;4:458-466. doi: 10.1182/bloodadvances.2019000776.
193. Lecumberri R, Krsnik I, Askari E, et al. Treatment with daratumumab in patients with relapsed/refractory AL amyloidosis: A multicentric retrospective study and review of the literature. *Amyloid.* 2020;27:163-167. doi: 10.1080/13506129.2020.1730791.
194. Kimmich CR, Terzer T, Benner A, et al. Daratumumab for systemic AL amyloidosis: Prognostic factors and adverse outcome with nephrotic-range albuminuria. *Blood*. 2020;135:1517-1530. doi: 10.1182/blood.2019003633.
195. Milani P, Fazio F, Basset M, et al. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate. *Am. J. Hematol.* 2020;95:900-905. doi: 10.1002/ajh.25828.
196. Cohen OC, Brodermann MH, Blakeney U, et al. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis. *Amyloid.* 2020;27:200-205. doi: 10.1080/13506129.2020.1765768.
197. Roccatello D, Fenoglio R, Naretto C, et al. Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience. *J. Clin. Med.* 2020;9:3232. doi: 10.3390/jcm9103232.
198. Shragai T, Gatt M, Lavie N, et al. Daratumumab for relapsed AL amyloidosis. When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review. *Eur. J. Haematol.* 2020. doi: 10.1111/ejh.13535.
199. Milani P, Basset M, Curci P, et al. Daratumumab in light chain deposition disease: rapid and profound hematologic response preserves kidney function. *Blood Adv.* 2020;4(7):1321-1324. doi: 10.1182/bloodadvances.2020001553.
200. Kastiris E, Rousakis P, Kostopoulos IV, et al. Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease. *Amyloid.* 2021;28(4):259-266. doi:10.1080/13506129.2021.1971192.
201. Zand L, Rajkumar SV, Leung N, et al. Safety and Efficacy of Daratumumab in Patients with Proliferative GN with Monoclonal Immunoglobulin Deposits. *J Am Soc Nephrol.* 2021;32(5):1163-1173. doi:10.1681/ASN.2020101541.
202. Dispenzieri A. Monoclonal gammopathies of clinical significance. *Hematology Am Soc Hematol Educ Program.* 2020;2020(1):380-?. doi: 10.1182/hematology.2020000122.